https://www.reuters.com/legal/ex-coinbase-managers-brother-sentenced-10-months-insider-trading-case-2023-01-10/
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19.4
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $19 to $19.4.